- Home
- MEGL vs THAR Comparison
MEGL vs THAR Comparison
Compare MEGL & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEGL
- THAR
- Stock Information
- Founded
- MEGL 2016
- THAR 2017
- Country
- MEGL Hong Kong
- THAR United States
- Employees
- MEGL N/A
- THAR N/A
- Industry
- MEGL Finance: Consumer Services
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- MEGL Finance
- THAR Health Care
- Exchange
- MEGL Nasdaq
- THAR Nasdaq
- Market Cap
- MEGL 6.8M
- THAR 5.5M
- IPO Year
- MEGL 2022
- THAR 2022
- Fundamental
- Price
- MEGL $1.33
- THAR $3.68
- Analyst Decision
- MEGL
- THAR Strong Buy
- Analyst Count
- MEGL 0
- THAR 1
- Target Price
- MEGL N/A
- THAR $17.00
- AVG Volume (30 Days)
- MEGL 27.8K
- THAR 29.2M
- Earning Date
- MEGL 10-29-2025
- THAR 11-06-2025
- Dividend Yield
- MEGL N/A
- THAR N/A
- EPS Growth
- MEGL N/A
- THAR N/A
- EPS
- MEGL N/A
- THAR N/A
- Revenue
- MEGL $1,645,862.00
- THAR N/A
- Revenue This Year
- MEGL N/A
- THAR N/A
- Revenue Next Year
- MEGL N/A
- THAR N/A
- P/E Ratio
- MEGL N/A
- THAR N/A
- Revenue Growth
- MEGL N/A
- THAR N/A
- 52 Week Low
- MEGL $1.02
- THAR $0.95
- 52 Week High
- MEGL $5.52
- THAR $9.08
- Technical
- Relative Strength Index (RSI)
- MEGL 39.06
- THAR 50.85
- Support Level
- MEGL $1.34
- THAR $4.94
- Resistance Level
- MEGL $1.50
- THAR $7.25
- Average True Range (ATR)
- MEGL 0.06
- THAR 1.50
- MACD
- MEGL -0.00
- THAR -0.08
- Stochastic Oscillator
- MEGL 15.00
- THAR 32.49
About MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.